


# Radiobiology in Brachytherapy

---

Prof Ramesh S Bilimagga  
M S Ramaiah Medical College  
Medical Director, HCG  
Bangalore





# Radiobiology

---

- For changing the fractionation schedules
- Change of dose rate systems (LDR/HDR)
- Gap correction
- Combining EBRT with Brachytherapy
- Choosing the right isotope
- Comparison of data between centres

- Experimental- Ram testis
- Stranquist Curves 1944
- NSD –Ellis 1969
- Orton TDF Brachytherapy 1974
- Elkind kind of repair
  - Inter Fr time, Dose/Fr, Dose Rate
- Cumulative Response Dose(CRE)
  - Kirk et al
- Tumor Significant Dose (TSD)






- It does not take all complex biological process
- Doubts on validity of NSD relation with tissue type
- Doubts on validity of NSD relation with different effect in same tissue type
- Range of number of fractions. The formula is provided
- Concern on the time factor taken.



# Radiobiology(RB)

---

- Dose Rate
- Fractionation
- Overall treatment time
- Biology Of Tumor (Radiosensitivity)
- Biology of Normal Tissue (sensitivity and repair mechanisms)




# Biological Models

---

- Linear Quadratic Model
  - Lea & Catcheside
- Various modifications of LQ model
- BED : Biological Equivalent dose
- EUD : Equivalent Uniform Dose

# L Q model



- It quantitatively predicts the dose/fraction dependence. The principal determinants are  $\alpha$  &  $\beta$
- $\alpha$  – Linear portion in Cell Survival Curve.
  - Occurs along a single ionizing tract
  - Tumor cells (rapid proliferation rates & short duration for repair)
- $\beta$  - Quadratic portion in Cell Survival Curve
  - Occurs along a two different ionising tracts
  - Normal cells (coordinated repair & hence requiring double hit)
- $\alpha/\beta$  ratio
  - Dose where there is proportionate of cell death due to linear & quadratic portions



# Interpretation of $\alpha/\beta$

---

- High  $\alpha/\beta$  ratio

For a particular dose of radiation either the

- $\alpha$  DNA injury is higher

or

- $\beta$  DNA injury is lower

- Low  $\alpha/\beta$  ratio

For a particular dose of radiation either the

- $\alpha$  DNA injury is lower

or

- $\beta$  DNA injury is Higher





# Pros & Cons

---

Low  $\alpha/\beta$  means

↓ in dose/fraction

less injury to normal tissue

High  $\alpha/\beta$  means

↑ in dose/fraction

More injury to normal tissue

- Limitations

Fractionated Rx delivered @ regular interval period (once in 24hrs) & 5Fr/Wk.

Gap in Rx in pt **NOT** considered



# Biological Effective Dose (BED)

---


- Concept used to compare the effectiveness of cell killing by different fractionation regimen by using LQ Model
- Use
  - Intercomparison of various RT schedules
  - Intercomparison of different types of radiotherapy
- Formula
  - = Total Physical dose [D] x Relative effectiveness [RE]



# Factors considered in BED

---

- Physical
  - Dose
  - Dose/fr
  - Inter fraction interval .
- Radiobiology
  - $\alpha/\beta$
  - Repair rate
  - T pot
  - Repopulation & Redistribution .
  - Overall treatment time



- BED differs for different normal tissue & also for different tumor biology
- BED is represented as numerical value of dose with suffix indicating the  $\alpha/\beta$  value.
- Eg: 100 BED<sub>3</sub>, 65 BED<sub>10</sub>
- Relative Effective factor  
= Phy Factor + RB Factor



# Repopulation



- RE for repopulation when taken into consideration uses subtractive repopulation correction factor w.r.t repopulation rate and Rx time.
- $BED = D \times RE - RCF$  (repopulation correction factor)
- $RCF = K (T - T_{\text{delay}})$   
 $T_{\text{delay}}$  is delay time after beginning of treatment before the repopulation rate becomes significant.

Eg: 28 days for HNSCC



# Differences

---



## EBRT

- Large Volume
- Homogeneous
- -5% to +7% acceptable
- Small dose, protracted time (weeks)
- Full repair

## Brachytherapy

- Isodose encircling a small target volume
- Very heterogenous
- High dose, short treatment (hours to days)
- Short interval (HDR), Continuously (LDR)



# LDR vs HDR


---



- Several Trials comparing LDR Vs HDR
  - Historical data
- Most cases similar results
- HDR beneficial with equivalent normal tissue tolerance & the tumoricidal doses
- Severe Complications
  - 3.44% ( $>7$  Gy) & 1.28% ( $<7$  Gy)

# Volume, Anatomical site


- The Dose reqd increases with size of tumor
- As Dose increases tolerance of late responding normal tissues decreases.





- [illegible]

# Reirradiation



- High doses can be delivered to previously irradiated area
- Can be tolerated if delivered to a limited volume. recovery seems to be less in some like CNS
- No clarity regarding minimal interval between two irradiations.



# Combined with EBRT



- Because BEDs are additive the determination of biological effects associated with combined modality treatments is straightforward.
- Total BED
$$= \text{BED}_{(\text{EBRT})} + \text{BED}_{(\text{Brachy})} - \text{RCF}$$


RCF (repopulation correction factor) is reqd only for tumor calculations and should be calculated using the overall treatment time of the combined treatments.
- In Brachytherapy calculation allowance for dose gradient effect. Should also be considered.



## The radiobiological models helps in

---

- Quantification of CLDR & FHDR
- Quantification of dose rate effect
- Quantification Permanent implants
- Quantification of PDR Brachytherapy
- Treatment intercomparison
- Designing new Fr & Rx schedules
- Calculating dose equivalence used with different isodose




# Future

- Commercially TPS incorporating biological models
  - Bioplan
  - Orbit
  - LQ Survivor









# Dose correction

---

- Recommended when dose rate  $> 1\text{Gyhr}$
- At 1.5-2Gyhr little differential effect is expected but fractionation (2-3Fr) compensates to some extent
- RB interpretation of clinical data should therefore combine dose rate & dose fractionation parameters.




## Dose conversion CLDR to FHDR

---

- $BED = \text{Total Dose} \times [1 + 2R / \mu \text{ (}\alpha/\beta \text{ ratio)}]$
- $R = \text{dose rate}, \mu = \text{Constant } .5$
- Eg 40 Gy in 48Hrs, BED<sub>10</sub> (Tumor) 3 (Late normal tissue) HDR
- $CLDR_{\text{tumor}} = 40 \times [1 + 2(40\text{Gy}/48\text{hr}) / .5 \times 10]$   
 $= 53.3\text{Gy}_{10}$
- $CLDR_{\text{normal}} = 40 \times [1 + 2(40\text{Gy}/48\text{hr}) / .5 \times 3]$ 
  - $84.4\text{Gy}_3$




- 
- $BED_{10} = 6 \text{ FHDR} = 53.3 \text{ Gy}$   
 $6d \times [1 + d/10] = 53.3 \text{ Gy}, d = 5.67 \text{ Gy}$
  - $HDR_{\text{normal}} = 34.02 \times [1 + 2(5.67/10)]$   
 $= 98.3 \text{ Gy}_{\text{HDR}}$

Compared to  $84.4 \text{ Gy}_{\text{LDR}}$

in order to achieve 10% less dose to normal tissue, equivalent to LDR then

- $HDR_{\text{normal}} = 34.02 \times [1 + 2(\{5.67 - 10\%\}/10)]$   
 $= 82.7 \text{ Gy}$



- In other words in order to achieve the same tumor control the dose as per HDR should be 5.67Fr.
- Dose to be reduced from 40 Gy  $>$  34.02 Gy
- Also in order to achieve the same normal tissue toxicity the dose as per HDR should be 5.1Gy/Fr instead of 5.67Fr without compromising on the tumor control